US EditionThe Best Stock Bet on Mrna – Who Is Ahead in the Biotech vs. Moderna Race
4 Articles
4 Articles
Biontech and Moderna achieved billions of profits with vaccines. Meanwhile, the boom business has broken in – and strategies are drifting apart. While Moderna adheres to the proven mRNA technology, Biontech invests in oncology. A clear winner is shown on the market.
Biontech became known for its corona vaccine. In the future, however, the Mainz-based company wants to make money with cancer treatments. In the coming months, billions will be spent on this.
After the success of his Corona vaccine, Biontech continues to conduct research on cancer therapies. Acquisitions and cooperations should keep potential competition at a distance.
After Corona, Biontech wanted to defeat cancer, but the rapid success can be expected. However, new quarterly figures are encouraging. How Germany's largest pharma hope reinvents itself
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
